Overview

Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) (ITGB3) is a gene that encodes a protein that participates in cell adhesion and cell-surface mediated signaling. Missense mutations, silent mutations, nonsense mutations, and frameshift deletions are observed in cancers such as skin cancer, endometrial cancer, and colon cancer.

ITGB3 is altered in 1.99% of all cancers with bladder urothelial carcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, high grade ovarian serous adenocarcinoma, and lung adenocarcinoma having the greatest prevalence of alterations [3].

The most common alterations in ITGB3 are ITGB3 A335V (10.00%), ITGB3 C432Y (0.22%), ITGB3 D267H (0.20%), ITGB3 E349A (0.39%), and ITGB3 E526Q (0.39%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.